carbostyril has been researched along with Progeria in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Avallone, H; Cao, K; Capell, BC; Chen, X; Collins, FS; Conneely, KN; Erdos, MR; Faddah, DA; Ganesh, SK; Kolodgie, FD; Nabel, EG; Olive, M; Qu, X; San, H; Tavarez, UL; Virmani, R | 1 |
Bendale, P; Gelb, MH; Huyer, G; Mallampalli, MP; Michaelis, S | 1 |
2 other study(ies) available for carbostyril and Progeria
Article | Year |
---|---|
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.
Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Mice; Progeria; Quinolones | 2008 |
Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
Topics: Amino Acid Motifs; Blotting, Western; Cell Nucleus; Fibroblasts; Green Fluorescent Proteins; HeLa Cells; Humans; Lamin Type A; Lipoproteins; Membrane Proteins; Metalloendopeptidases; Metalloproteases; Mutation; Nuclear Proteins; Progeria; Protein Precursors; Protein Prenylation; Quinolones | 2005 |